Lancet Onco:前列腺癌新疗法可减少副作用

2012-04-20 黄堃 新华网

4月17日,英国伦敦大学学院等机构研究人员在医学刊物《柳叶刀—肿瘤学》The Lancet Oncology上报告说,他们开发出利用超声波治疗前列腺癌的新方法,可大幅减少尿失禁、性功能障碍等副作用。 研究者的这种疗法的原理是,在用磁共振成像等技术确定肿瘤位置后,用高度集中的超声波照射肿瘤细胞,将其加热并杀死。其优点是超声波可集中在只有一个米粒大小的目标部位,在杀死肿瘤细胞同时不影响周围的

4月17日,英国伦敦大学学院等机构研究人员在医学刊物《柳叶刀—肿瘤学》The Lancet Oncology上报告说,他们开发出利用超声波治疗前列腺癌的新方法,可大幅减少尿失禁、性功能障碍等副作用。
 
研究者的这种疗法的原理是,在用磁共振成像等技术确定肿瘤位置后,用高度集中的超声波照射肿瘤细胞,将其加热并杀死。其优点是超声波可集中在只有一个米粒大小的目标部位,在杀死肿瘤细胞同时不影响周围的健康组织,从而减少副作用。
 
治疗前列腺癌的传统方法,比如放射疗法或手术切除,常会影响整个前列腺部位,从而导致许多副作用,比如尿失禁、性功能障碍和肠道出血等。不出现这些副作用且治疗后一年内病情都能得到控制的成功率仅50%左右。
 
在本次临床试验中,41名前列腺癌患者接受了新疗法治疗,没有人出现尿失禁,出现性功能障碍者只有约十分之一。
 
领导研究的哈希姆·艾哈迈德说,本次试验的结果非常令人鼓舞,接下来还会进行更大规模的临床试验,争取尽早为前列腺癌患者正式提供这种新疗法,帮助他们提高生活质量。

doi:10.1016/S1470-2045(12)70121-3
PMC:
PMID:

Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study

Dr Hashim U Ahmed MRCS a b , Richard G Hindley FRCS e, Louise Dickinson MRCS a b, Alex Freeman FRCPath c, Alex P Kirkham FRCR d, Mahua Sahu MRCS b, Rebecca Scott RN a, Clare Allen FRCR d, Prof Jan Van der Meulen PhD f g, Prof Mark Emberton FRCS a

Background Radical whole-gland therapy can lead to significant genitourinary and rectal side-effects for men with localised prostate cancer. We report on whether selective focal ablation of unifocal and multifocal cancer lesions can reduce this treatment burden. Methods Men aged 45—80 years were eligible for this prospective development study if they had low-risk to high-risk localised prostate cancer (prostate specific antigen [PSA] ≤15 ng/mL, Gleason score ≤4 + 3, stage ≤T2), with no previous androgen deprivation or treatment for prostate cancer, and who could safely undergo multiparametric MRI and have a general anaesthetic. Patients received focal therapy using high-intensity focused ultrasound, delivered to all known cancer lesions, with a margin of normal tissue, identified on multiparametric MRI, template prostate-mapping biopsies, or both. Primary endpoints were adverse events (serious and otherwise) and urinary symptoms and erectile function assessed using patient questionnaires. Analyses were done on a per-protocol basis. This study is registered with ClinicalTrials.gov, number NCT00561314. Findings 42 men were recruited between June 27, 2007, and June 30, 2010; one man died from an unrelated cause (pneumonia) 3 months after treatment and was excluded from analyses. After treatment, one man was admitted to hospital for acute urinary retention, and another had stricture interventions requiring hospital admission. Nine men (22%, 95% CI 11—38) had self-resolving, mild to moderate, intermittent dysuria (median duration 5·0 days [IQR 2·5—18·5]). Urinary debris occurred in 14 men (34%, 95% CI 20—51), with a median duration of 14·5 days (IQR 6·0—16·5). Urinary tract infection was noted in seven men (17%, 95% CI 7—32). Median overall International Index of Erectile Function-15 (IIEF-15) scores were similar at baseline and at 12 months (p=0·060), as were median IIEF-15 scores for intercourse satisfaction (p=0·454), sexual desire (p=0·644), and overall satisfaction (p=0·257). Significant deteriorations between baseline and 12 months were noted for IIEF-15 erectile (p=0·042) and orgasmic function (p=0·003). Of 35 men with good baseline function, 31 (89%, 95% CI 73—97) had erections sufficient for penetration 12 months after focal therapy. Median UCLA Expanded Prostate Cancer Index Composite (EPIC) urinary incontinence scores were similar at baseline as and 12 months (p=0·045). There was an improvement in lower urinary tract symptoms, assessed by International Prostate Symptom Score (IPSS), between baseline and 12 months (p=0·026), but the IPSS-quality of life score showed no difference between baseline and 12 months (p=0·655). All 38 men with no baseline urinary incontinence were leak-free and pad-free by 9 months. All 40 men pad-free at baseline were pad-free by 3 months and maintained pad-free continence at 12 months. No significant difference was reported in median Trial Outcomes Index scores between baseline and 12 months (p=0·113) but significant improvement was shown in median Functional Assessment of Cancer Therapy (FACT)-Prostate (p=0·045) and median FACT-General scores (p=0·041). No histological evidence of cancer was identified in 30 of 39 men biopsied at 6 months (77%, 95% CI 61—89); 36 (92%, 79—98) were free of clinically significant cancer. After retreatment in four men, 39 of 41 (95%, 95% CI 83—99) had no evidence of disease on multiparametric MRI at 12 months. Interpretation Focal therapy of individual prostate cancer lesions, whether multifocal or unifocal, leads to a low rate of genitourinary side-effects and an encouraging rate of early absence of clinically significant prostate cancer. Funding Medical Research Council (UK), Pelican Cancer Foundation, and St Peters Trust.

作者:黄堃



版权声明:
本网站所有注明“来源:梅斯医学”或“来源:MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明“来源:梅斯医学”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. 2021-11-20 湘雅科教

    已阅,受益匪浅。

    0

  2. 2012-12-06 howi

相关资讯

局限期前列腺癌根治性放疗的靶区勾画提出参考性建议

 随着人均寿命的延长,我国老年人口的不断增加,前列腺癌的发病率逐年上升。放疗是前列腺癌根治性治疗手段之一,从局限低、中、高危前列腺癌到盆腔淋巴结转移,甚至远处转移前列腺癌,放疗均有广泛的应用。对于局限期前列腺癌,放疗可取得与手术相当的疗效且并发症的发生较少。   近年来,随着各种放疗新技术的出现和发展,前列腺癌的放疗越来越准确,正常组织的保护则更可靠,因此,接受放疗的患者越来越多。我们参照美国

根治性放疗用于前列腺癌证据集锦

  前列腺癌放疗历史回顾   放疗疗效与临床分期、格里森(Gleason)评分、治疗前前列腺特异性抗原(PSA)水平和照射剂量有关。 早期的放疗技术为四野箱式常规照射,前列腺区的剂量一般为64~68 Gy。   1979年 泰勒(Taylor)报道,36例B期前列腺癌放疗后的5年生存率为68.8%。   1986年 佩雷斯(Perez)报道,343例前列腺癌患者接受60~70 Gy照射,A2

PNAS:美新药有望治愈近十种癌症

       据英国《每日邮报》3月26日报道,美国科学家日前研制出了一种能帮助人体免疫系统摧毁癌细胞的新型药物,对乳腺癌、肠癌、前列腺癌、子宫癌、脑癌、膀胱癌、肝癌等多种癌症都有疗效。此外前期研究表明,该药物还可用于治疗血癌(白血病)。研究人员表示,若能及早使用,该药物甚至可以完全治愈恶性肿瘤疾病,且副作用极小。(Proc Natl Acad Sci U

前列腺癌根治性放疗证据集萃及建议

       作者:中国医学科学院肿瘤医院放疗科 房辉 刘跃平 王维虎 李晔雄        前言        前列腺癌是老年男性常见的恶性肿瘤。放疗是早期和局部晚期前列腺癌的根治性治疗手段;对局限期(T1~2)前列腺癌患者,放疗与手术疗效相当;对局部晚期(

英开发前列腺癌新疗法减少副作用

英国研究人员4月17日报告说,他们开发出利用超声波治疗前列腺癌的新方法,可大幅减少尿失禁、性功能障碍等副作用。   英国伦敦大学学院等机构研究人员在医学刊物《柳叶刀—肿瘤学》上报告说,这种疗法的原理是,在用磁共振成像等技术确定肿瘤位置后,用高度集中的超声波照射肿瘤细胞,将其加热并杀死。其优点是超声波可集中在只有一个米粒大小的目标部位,在杀死肿瘤细胞同时不影响周

PNAS:侵袭性前列腺癌的人类基因组研究

据一项在线发表在PNAS杂志上的研究证实:前列腺癌的发展相关联的人类基因组中存在两个遗传基因的缺失。 布里格姆妇女医院Weill Cornell医学学院的研究人员和因斯布鲁克大学医院合作研究揭示男人发展患有前列腺癌取决于他们所继承的遗传变异。 研究人员发现一个影响已知基因功能的基因缺失,以前认为其他基因的缺失是“垃圾DNA”,但基因组非编码区似乎控制基因的级联。 研究结果表明蛋白质编码或非人